DNA X, Inc. (SONM) stock
SONMNasdaqTelephone & Telegraph ApparatusFiscal year ends December 31
$2.38+0.10 (+4.39%)
Close on Nov 12, 2026Market cap $3.54MP/E –Yield –
DNA X EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
DNA X's EPS for the twelve months ending Jun 30, 2026 was -$9.24. For fiscal 2025 it was -$28.58. The highest annual figure on record is -$0.36 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$28.58 | – |
| FY2024 | Dec 31, 2024 | -$128.37 | – |
| FY2023 | Dec 31, 2023 | -$0.36 | – |
| FY2022 | Dec 31, 2022 | -$85.26 | – |
| FY2021 | Dec 31, 2021 | -$709.92 | – |
| FY2020 | Dec 31, 2020 | -$1127.52 | – |
| FY2019 | Dec 31, 2019 | -$2418.60 | – |
| FY2018 | Dec 31, 2018 | -$4471.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.92 | – |
| Q1 FY2026 | Mar 31, 2026 | $5.01 | +255.3% |
| Q4 FY2025 | Dec 31, 2025 | -$8.50 | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.83 | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.15 | – |
| Q1 FY2025 | Mar 31, 2025 | $1.41 | – |
| Q4 FY2024 | Dec 31, 2024 | -$79.43 | -3777.3% |
| Q3 FY2024 | Sep 30, 2024 | -$9.32 | -570.7% |
| Q2 FY2024 | Jun 30, 2024 | -$25.38 | -1558.6% |
| Q1 FY2024 | Mar 31, 2024 | -$11.70 | – |
| Q3 FY2023 | Sep 30, 2023 | $2.16 | – |
| Q2 FY2023 | Jun 30, 2023 | $1.98 | – |
| Q1 FY2023 | Mar 31, 2023 | $1.74 | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.96 | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.28 | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.12 | – |
| Q4 FY2021 | Dec 31, 2021 | -$125.98 | – |
| Q3 FY2021 | Sep 30, 2021 | -$227.94 | – |
| Q2 FY2021 | Jun 30, 2021 | -$174.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$243.60 | – |
| Q4 FY2020 | Dec 31, 2020 | -$168.04 | – |
| Q1 FY2020 | Mar 31, 2020 | -$835.20 | – |
| Q4 FY2019 | Dec 31, 2019 | -$719.49 | – |
| Q3 FY2019 | Sep 30, 2019 | -$574.20 | – |
| Q2 FY2019 | Jun 30, 2019 | -$539.40 | – |
| Q1 FY2019 | Mar 31, 2019 | -$556.80 | – |
| Q3 FY2018 | Sep 30, 2018 | -$1583.40 | – |
| Q2 FY2018 | Jun 30, 2018 | -$5237.40 | – |
| Q1 FY2018 | Mar 31, 2018 | -$13519.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?